U.S. Luxury Stock News

In late February 2026, Axos Financial, a digital-focused US bank, was caught in a broad financial sector downturn after a higher-than-expected January Producer Price Index reading reinforced concerns about persistent inflation and constrained room for near-term Federal Reserve rate cuts. This inflation surprise matters for Axos because sustained elevated rates can pressure bank net interest margins, directly affecting how profitably it turns deposits into loans and other interest-earning...

Agree Realty (ADC) has drawn attention after its recent share performance, with the stock last closing at $80.48. For income focused investors, the real estate investment trust’s profile may warrant a closer look. See our latest analysis for Agree Realty. The recent 11.8% 1 month share price return, on top of an 11.6% year to date share price return, sits alongside a 5 year total shareholder return of 54.4%, suggesting momentum has been building over both shorter and longer horizons. If this...

Xponential Fitness (XPOF) is back in focus after reporting fourth quarter and full year 2025 results, along with 2026 revenue guidance that points to a lower range than the prior year. See our latest analysis for Xponential Fitness. The earnings release and lower 2026 revenue guidance have coincided with sharp share price weakness, with a 1 day share price return of 47.08% decline and a 1 year total shareholder return of 67.75% decline. This points to fading momentum and a reassessment of...

In recent days, Cathay General Bancorp has come under pressure as investors reacted to rising credit risk concerns amid hotter-than-expected inflation data and growing worries over regional banks’ exposure to commercial real estate. What makes this episode especially important is that it coincides with Cathay General’s flat sales and declining earnings per share, sharpening questions about its profitability and growth profile. We’ll now examine how heightened credit risk concerns,...

Earnings, guidance and capital returns in focus Bristow Group (VTOL) just paired its fourth quarter and full year 2025 results with 2026 guidance, a fresh quarterly dividend and details on a recent US$500 million refinancing at a lower coupon. The company reported Q4 2025 sales of US$377.26 million and net income of US$18.42 million, while affirming 2026 revenue expectations in a US$1.58 billion to US$1.69 billion range and maintaining its new US$0.125 quarterly cash dividend. See our latest...

In February 2026, Federal Agricultural Mortgage Corporation reported fourth-quarter 2025 net income of US$47.92 million, down from US$56.51 million a year earlier, while full-year net income was broadly flat at US$207.42 million, and its board approved higher dividends on both common and preferred shares. Beyond the headline earnings softness, Farmer Mac’s fifteenth consecutive annual increase in its common dividend, alongside growth in infrastructure finance such as broadband and renewable...

Manchester United plc has reported fiscal second-quarter 2026 results, with sales of £190.31 million and a net income of £4.18 million, marking a return to profit despite lower revenue than the same period a year ago. The earnings improvement stems largely from cost and headcount reductions that turned a prior-period loss into a profit, while management reiterated full-year revenue guidance of £640 million to £660 million. We’ll now look at how this cost-driven profitability turnaround,...

If you are wondering whether Spectrum Brands Holdings is still attractively priced or already reflecting its potential, you are in the right place for a clear, valuation focused look at the stock. The share price recently closed at US$78.38, with returns of 23.0% over 30 days and 30.5% year to date, while the 1 year return sits at 4.4% and the 3 and 5 year returns are 28.8% and 8.8% respectively. This naturally raises questions about how much value is already priced in. Recent news around...

Claritev Corporation recently reported past fourth-quarter 2025 sales of US$246.55 million and a net loss of US$80.57 million, alongside full-year 2025 sales of US$965.41 million and a net loss of US$284.28 million, and announced a new share repurchase program of up to US$75 million running through 2030. While the company remains loss-making, the year-on-year reduction in losses and the commitment to buying back shares suggest management is focused on improving financial discipline and...

Glaukos (GKOS) is back in focus after its fourth quarter 2025 report paired strong sales figures with a sizeable impairment charge, followed shortly by fresh 2026 sales guidance and a new ESOP related shelf registration. See our latest analysis for Glaukos. The recent impairment charge and ESOP related shelf registration come against a backdrop of steady share price gains, with a 90 day share price return of 13.28% and a very large 3 year total shareholder return of 139.03%. This suggests...

Xeris Biopharma recently filed a Hatch-Waxman patent infringement lawsuit in the US District Court for the District of New Jersey against Torrent Pharmaceuticals and Somerset Therapeutics, seeking to block generic versions of its Cushing’s syndrome therapy Recorlev until its patents expire in March 2040. This legal move highlights how central Recorlev’s intellectual property protection is to Xeris’s long-term product exclusivity and potential revenue longevity in its endocrine...

Omnicell has recently accelerated its shift from hardware-focused sales toward software and services, including acquiring ANiGENT in October 2025 to broaden its drug diversion detection capabilities and recurring revenue base. This pivot toward subscription-like revenue streams is prompting investors to reassess Omnicell less as a traditional equipment maker and more as a healthcare IT provider, with different expectations for growth, risk and valuation. Next, we’ll examine how Omnicell’s...

Arcosa (ACA) is back on investors’ radar after a recent share pullback over the past week and month, drawing attention to how its infrastructure focused business and current valuation metrics stack up today. See our latest analysis for Arcosa. The sharp 1 day share price decline of 15.7% and 7 day share price return of 14.9% sit against a 1 year total shareholder return of 28.42% and 5 year total shareholder return of 84.39%. This suggests recent momentum has cooled after a strong multi year...

In February 2026, Ladder Capital Corp. announced it had secured US$675 million in new unsecured capital commitments, expanding its unsecured revolving credit facility to US$1.25 billion and adding a US$275 million unsecured delayed draw term loan priced at 140 basis points over SOFR. This package of same-day liquidity at 125 basis points over SOFR and long-dated funding to 2030 materially strengthens Ladder’s funding flexibility and duration profile. Next, we’ll examine how this expanded...

Owens Corning (NYSE:OC) reported a net loss for the fourth quarter, reversing net income from the same period a year earlier. The company also posted a full year net loss, a material deterioration compared with the prior year's profitability. Recent results came in below earnings expectations, highlighting weaker than anticipated financial performance. For investors watching NYSE:OC, this shift to losses comes with the stock recently closing at $122.07. Shares are down 8.0% over the past...

If you are wondering whether Boise Cascade's share price still reflects its real worth, looking at how the market has treated the stock over different time frames is a useful starting point. The stock last closed at US$82.74, with returns of 0.7% over 7 days, 3.0% over 30 days, 11.6% year to date, but a 19.3% decline over 1 year and longer term returns of 36.4% over 3 years and 107.2% over 5 years. Recent headlines around Boise Cascade have focused on its position as a major supplier of...

FDA lifts clinical hold on Intellia Therapeutics' MAGNITUDE-2 ATTR amyloidosis trial, allowing global enrollment to resume with updated safety protocols. Intellia completes phase 3 enrollment ahead of schedule in the HAELO trial for lonvo-z, a one time gene editing therapy for hereditary angioedema. These steps advance Intellia Therapeutics' late stage pipeline and move its gene editing candidates closer to potential approval and commercialization. For investors watching Intellia...

If you are trying to work out whether Lineage at around US$40.52 is a bargain or just fairly priced, you are in the right place. The stock has recently posted returns of 5.8% over 7 days, 12.6% over 30 days and 14.4% year to date, although the 1 year return sits at a 29.3% decline. Recent attention on Lineage has focused on its position in the US real estate space and how investors are reassessing companies in the sector, which helps frame these recent price moves. Coverage has regularly...

Hyatt Hotels (NYSE:H) announced the retirement of Executive Chairman Thomas J. Pritzker after more than two decades in the role. The move comes alongside public mention of Pritzker's past association with Jeffrey Epstein and Ghislaine Maxwell. Hyatt has appointed current CEO Mark S. Hoplamazian as the new Chairman, concentrating leadership in a single figure. The transition highlights both succession planning and governance considerations for the company. For you as an investor, the key...

Why Aspen Aerogels is back in focus Aspen Aerogels (ASPN) is back on investors’ radar after reporting a sharp year over year revenue decline, a large full year net loss, a sizeable impairment charge, and guidance indicating continued losses. See our latest analysis for Aspen Aerogels. The stock’s recent swings reflect this reset in expectations, with a 7 day share price return showing a 13.57% decline and a 1 year total shareholder return indicating a 59% loss, highlighting how pressure has...

Xcel Energy (NasdaqGS:XEL) announced a new partnership with Google to support a major data center project. The development includes what is described as the world's largest iron air battery installation to support clean energy use and grid reliability. Xcel Energy plans to structure the project so that existing customers are not impacted by the data center's large power needs. The company also appointed Rob Cain as Chief Technology Officer, with responsibility for driving technology and...

If you are wondering whether Amer Sports at around US$37.98 is offering good value or not, you are not alone. This article is here to unpack that question clearly. The stock has had a mixed run, with a 9.5% decline over the last 7 days, a 3.7% gain over the past month, and a 27.1% return over the last year, which can change how investors think about both upside and risk. Recent news coverage has focused on Amer Sports as a consumer durables name that investors are watching for how it...

If you are wondering whether Parsons at around US$66 still offers value, or if the easy gains are already behind it, this article is for you. Parsons' share price sits at about US$66 after a 0.7% return over the last week, a 1 month return showing an 8.0% decline, and longer term returns of 6.1% year to date, 13.4% over 1 year, 45.3% over 3 years, and 80.7% over 5 years. These moves have put Parsons on the radar of investors who are watching how its government and infrastructure work is...

MannKind Corporation reported past fourth-quarter 2025 results with revenue rising to US$111.96 million, but swinging from prior net income to a US$15.95 million net loss, while full-year 2025 revenue increased to US$348.97 million alongside a lower net income of US$5.86 million. A key risk emerged as partner United Therapeutics recently unveiled a competing soft-mist treprostinil inhaler that could challenge MannKind’s Tyvaso DPI royalty stream, increasing uncertainty around the company’s...